Thus, the serum levels of TNF-α and IL-6 have been proposed as prognostic parameters for patients suffering septic shock [27,28], and immunotherapy using anti-TNF-α or anti-IL-6 monoclonal antibodies, such as afelimomab and tocilizumab, have reduced overall mortality from severe sepsis [29,30]. Here, IL6 is linked to Sepsis.